SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:prod.swepub.kib.ki.se:138854508"
 

Search: onr:"swepub:oai:prod.swepub.kib.ki.se:138854508" > PP2A inhibition is ...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells

Kauko, O (author)
O'Connor, CM (author)
Kulesskiy, E (author)
show more...
Sangodkar, J (author)
Aakula, A (author)
Izadmehr, S (author)
Yetukuri, L (author)
Yadav, B (author)
Padzik, A (author)
Laajala, TD (author)
Haapaniemi, P (author)
Momeny, M (author)
Varila, T (author)
Ohlmeyer, M (author)
Aittokallio, T (author)
Wennerberg, K (author)
Narla, G (author)
Westermarck, J (author)
show less...
American Association for the Advancement of Science (AAAS), 2018
2018
English.
In: Science translational medicine. - : American Association for the Advancement of Science (AAAS). - 1946-6242 .- 1946-6234. ; 10:450
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Pharmacological PP2A activation is a druggable approach to overcome MEK inhibitor resistance.

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view